Connect with us
MARE BALTICUM Gaming & TECH Summit 2024

Artificial Intelligence

Bispecific Antibody Clinical Trial Pipeline Appears Robust With 250+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

Published

on

bispecific-antibody-clinical-trial-pipeline-appears-robust-with-250+-key-pharma-companies-actively-working-in-the-therapeutics-segment-|-delveinsight

The bispecific antibody pipeline and clinical trial analysis report deliver important insights on ongoing research, clinical strategies, upcoming therapeutics, and commercial analysis. 
LAS VEGAS, July 3, 2023 /PRNewswire/ — DelveInsight’s ‘Bispecific Antibody Competitive Landscape – 2023′ report provides comprehensive global coverage of available, marketed, and pipeline bispecific antibodies in various stages of clinical development, major pharmaceutical companies working to advance the pipeline space, company assessment, comparative assessment, and future growth potential of the bispecific antibody competitive domain.
Key Takeaways from the Bispecific Antibody Competitive Landscape Report
Over 250+ bispecific antibody companies are evaluating 300+ bispecific antibody drugs in various stages of development, and their anticipated acceptance in the bispecific antibody market would significantly increase market revenue. Key bispecific antibody companies such as Janssen, Amgen, Akeso, Zymeworks, Roche, IGM Biosciences, MacroGenics, Provention Bio, Jiangsu Alphamab Biopharmaceuticals, Sichuan Baili Pharmaceutical, Regeneron Pharmaceuticals, Boehringer Ingelheim, and others are evaluating new bispecific antibody drugs to improve the treatment landscape.Promising bispecific antibody pipeline drugs such as Amivantamab, Blinatumomab, Ivonescimab, Zanidatamab, Glofitamab, Imvotamab, MGD024, PRV 3279, KN-046, SI-B001, REGN-5458, BI-905711, and others are under different phases of bispecific antibody clinical trials.In April 2023, Lonza signed an agreement with ABL Bio focusing on bispecific antibodies for immuno-oncology and neurodegenerative diseases. The collaboration is intended to help in the development and manufacturing of ABL Bio’s new bispecific antibody product.In March 2023, InvoX Pharma Limited announced that F-star, an invoX company, entered into a second license agreement with Takeda for a novel next-generation immuno-oncology bispecific antibody. Under the terms of the license agreement, F-star will grant Takeda a worldwide, exclusive royalty-bearing license to research, develop, and commercialize a bispecific antibody directed towards an undisclosed immuno-oncology target using F-star’s proprietary Fcab™ and mAb2 platforms. Takeda will be responsible for all research, development, and commercialization activities under the agreement. F-star will receive an undisclosed upfront license fee and is eligible to receive potential future development and commercialization milestone payments, plus royalties on annual net sales.In January 2023, Caris Life Sciences and Xencor, Inc. announced an expansion of their collaboration to research, develop and commercialize novel XmAb® bispecific and multi-specific antibodies directed against novel targets, identified and proposed by Caris, for the treatment of patients with cancer.In December 2022, Akeso announced a collaboration and license agreement with Summit Therapeutics Inc., to out-license its breakthrough bispecific antibody, ivonescimab (PD-1/VEGF, AK112) for development and commercialization in the United States, Canada, Europe, and Japan. In addition, the Company will co-brand the product in the License Territories.In December 2022, Biogen announced that it had reached an agreement with Genentech, a member of the Roche Group, related to the commercialization and sharing of economics for glofitamab. Under the terms of the agreement, Biogen will have no payment obligations and will receive tiered royalties on potential net sales of glofitamab within the United States as part of the companies’ long-standing collaboration on antibodies targeting CD20.In November 2022, IGM Biosciences and ADC Therapeutics announced that they had entered into a clinical trial collaboration and supply agreement to evaluate the combination of imvotamab, IGM’s novel IgM CD20 x CD3 T cell engaging bispecific antibody, and ZYNLONTA® (loncastuximab tesirine-lpyl), ADC Therapeutics’ CD19-directed antibody-drug conjugate (ADC), for the treatment of patients with relapsed/refractory (R/R) B cell non-Hodgkin’s lymphoma (NHL).In November 2022, Nona Biosciences announced that it had entered into a collaboration agreement with Dragonfly Therapeutics based on Nona’s proprietary fully human heavy chain only antibody (HCAb) transgenic mice platform to discover and develop fully human heavy chain only antibodies for bispecific/multi-specific therapeutic antibody generation.In October 2022, Jazz Pharmaceuticals and Zymeworks Inc. entered into an exclusive licensing agreement under which Jazz will acquire development and commercialization rights to Zymeworks’ zanidatamab across all indications in the United States, Europe, Japan, and all other territories except for those Asia/Pacific territories previously licensed by Zymeworks.In October 2022, Gilead Sciences and MacroGenics announced an exclusive option and collaboration agreement to develop MGD024, an investigational, bispecific antibody that binds CD123 and CD3 using MacroGenics’ DART® platform, and two additional bispecific research programs. The collaboration agreement grants Gilead the option to license MGD024, a potential treatment for certain blood cancers, including acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).Request a sample and discover the recent advances in bispecific antibody treatment @ Bispecific Antibody Competitive Landscape Report
Bispecific Antibody Overview
Bispecific antibodies have been developed, with one antigen-binding site directed against the CD3 receptor (which activates cytotoxic T lymphocytes) and the other directed against tumor cell antigens (CD19, CD20, CD33, CD123, HER2, epithelial cell adhesion molecule [EpCAM], BCMA, CEA, and others). The interaction with cytotoxic T lymphocytes and tumor cells caused by Bispecific antibody binding stimulates cytotoxic T cells and enhances tumor cell death. Several bispecific molecules for the treatment of different diseases have been produced in addition to a large spectrum of bispecific antibodies directed against tumors. The osteoporosis bispecific antibody inhibits the Wnt signal-transduction pathway factors (sclerostin and Dkk1), promoting osteoblast development and bone tissue growth.
Bispecific antibodies have various advantages over monospecific antibodies. Bispecific antibodies lead immune system effectors to tumor cells, increasing their cytotoxicity. Bispecific antibodies have higher binding specificity than monospecific antibodies because they engage with two separate surface antigens. When compared to combination therapy with two monospecific medicines, the use of bispecific antibodies allows for cost optimization by lowering the cost of development and clinical trials.
Find out more about bispecific antibody drugs @ Bispecific Antibody Treatment
Bispecific Antibody Pipeline Analysis: Drug Profile
Ivonescimab: Akeso
Ivonescimab, also known as AK112 in China and Australia and SMT112 in the Licence Territories, is a new, potentially first-in-class bispecific antibody that the Company created independently. Ivonescimab combines the immunotherapy benefits of PD-1 blockage with the anti-angiogenesis properties of an anti-VEGF into a single drug. The unique design, we believe, has the potential to lessen side effects and safety concerns. Ivonescimab is thought to be the most advanced PD-1 / VEGF bispecific antibody in the clinic: no known PD-1-based bispecific antibodies have been licensed by the FDA or the EMA. 
Akeso is currently running a phase III clinical research comparing ivonescimab monotherapy to pembrolizumab monotherapy as a first-line treatment for NSCLC patients with positive PD-L1 expression. In addition, phase III clinical research comparing Ivonescimab with chemotherapy to chemotherapy in EGFR-mutated advanced non-squamous NSCLC that had previously failed EGFR-TKI therapy is now underway. The NMPA has granted ivonescimab breakthrough therapy designation status in China for three indications: the two aforementioned indications, as well as when combined with docetaxel for the treatment of patients with locally advanced or metastatic NSCLC who have failed prior PD-(L)1 inhibitor combined with platinum-based doublet chemotherapy.
Zanidatamab: Zymeworks
Zanidatamab is a bispecific antibody based on Zymeworks’ Azymetric platform that can bind two non-overlapping HER2 epitopes at the same time, a process known as biparatopic binding. This one-of-a-kind design results in a variety of modes of action, including dual HER2 signal blockage, enhanced binding and removal of HER2 protein from the cell surface, and potent effector function, all of which contribute to encouraging anticancer activity in patients. Zymeworks is testing zanidatamab in several Phase I, Phase II, and pivotal clinical trials around the world as a targeted therapeutic option for patients with HER2-positive solid tumors.
A snapshot of the Bispecific Antibody Pipeline Drugs mentioned in the report:
Bispecific Antibody Drugs
Company
Phase 
Indication
Ivonescimab
Akeso
Phase III
Non-small cell lung cancer
Zanidatamab
Zymeworks
Phase III
Oesophageal cancer
Erfonrilimab 
Alphamab
Phase III
Non-small cell lung cancer; Pancreatic cancer
SI-B001
Sichuan Baili Pharmaceutical/SystImmune
Phase II/III
Non-small cell lung cancer
Glofitamab
Roche
Phase II
Follicular lymphoma; Mantle-cell lymphoma; Non-Hodgkin’s lymphoma
Imvotamab
IGM Biosciences
Phase II
Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma
PRV 3279
Hangzhou Zhongmei Huadong Pharmaceutical/Provention Bio
Phase II
Systemic lupus erythematosus
Linvoseltamab 
Regeneron Pharmaceuticals
Phase II
Multiple myeloma
MGD024
MacroGenics
Phase I
Hematological malignancies
BI-905711
Boehringer Ingelheim
Phase I
Colorectal cancer; Gastric cancer; Pancreatic cancer
 
Learn more about the emerging bispecific antibody pipeline drugs @ Bispecific Antibody Clinical Trials
Scope of the Bispecific Antibody Competitive Landscape Report 
Coverage: Global Key Bispecific Antibody Companies: Janssen, Amgen, Akeso, Zymeworks, Roche, IGM Biosciences, MacroGenics, Provention Bio, Jiangsu Alphamab Biopharmaceuticals, Sichuan Baili Pharmaceutical, Regeneron Pharmaceuticals, Boehringer Ingelheim, and othersKey Bispecific Antibody Pipeline Drugs: Amivantamab, Blinatumomab, Ivonescimab, Zanidatamab, Glofitamab, Imvotamab, MGD024, PRV 3279, KN-046, SI-B001, REGN-5458, BI-905711, and othersCompany Analysis, Therapeutic Assessment, Pipeline Assessment, Inactive drugs assessment, Unmet NeedsDive deep into rich insights for new bispecific antibody drugs, visit @ Bispecific Antibody Drugs
Table of Contents
1.
Bispecific Antibody Pipeline Report Introduction
2.
Bispecific Antibody Pipeline Report Executive Summary
3.
Bispecific Antibody Pipeline: Overview
4.
Bispecific Antibody Marketed Drugs 
4.1.
Amivantamab: Janssen
5.
Bispecific Antibody Clinical Trial Therapeutics
6.
Bispecific Antibody Pipeline: Late-Stage Products (Pre-registration)
7.
Bispecific Antibody Pipeline: Late-Stage Products (Phase III)
7.1.
Ivonescimab: Akeso
8.
Bispecific Antibody Pipeline: Mid-Stage Products (Phase II)
8.1.
Imvotamab: IGM Biosciences
9.
Bispecific Antibody Pipeline: Early-Stage Products (Phase I)
9.1.
MGD024: MacroGenics
10.
Bispecific Antibody Pipeline Therapeutics Assessment
11.
Inactive Products in the Bispecific Antibody Pipeline
12.
Company-University Collaborations (Licensing/Partnering) Analysis
13.
Unmet Needs
14.
Bispecific Antibody Market Drivers and Barriers
15.
Appendix
 
For further information on the bispecific antibody pipeline therapeutics, reach out @ Bispecific Antibody Analysis
Related Reports
Monoclonal Antibodies Competitive Landscape
Monoclonal Antibodies Competitive Landscape – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key monoclonal antibody companies, including Novartis, Gmax Biopharm, Omeros Corporation, Merck Sharp & Dohme, Disc Medicine, Eledon Pharmaceuticals, Alexion AstraZeneca Rare Disease, Chinook Therapeutics, Omeros Corporation, among others.
PD-1 and PD-L1 Inhibitors Competitive Landscape
PD-1 and PD-L1 Inhibitors Competitive Landscape – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key PD-1 and PD-L1 inhibitors companies, including Merck, Laekna Therapeutics, Genentech, Tracon Pharmaceuticals Inc., Celgene, MedImmune, Hangzhou Sumgen Biotech, Lepu Biopharma, Harbour BioMed, Curis, BeiGene, Apollomics, Agenus, Boehringer Ingelheim, Jounce Therapeutics, Seagen Inc., Ascletis Pharma Inc., Secarna Pharmaceuticals GmbH & Co. KG, Arbutus Biopharma, among others.
JAK Inhibitors Competitive Landscape
JAK Inhibitors Competitive Landscape – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key JAK inhibitors companies, including Pfizer, Sierra Oncology, Theravance Biopharma, Dizal Pharmaceutical, Aclaris Therapeutics, Celon Pharma, Incyte Corporation, AbbVie, Galapagos, among others.
TIGIT Inhibitors Competitive Landscape
TIGIT Inhibitors Competitive Landscape – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key TIGIT inhibitors companies, including Merck Sharp & Dohme, Bristol-Myers Squibb, BeiGene, Arcus Biosciences, iTeos Therapeutics, Mereo BioPharma, Phio Pharmaceuticals, Bio-Thera Solutions, Compugen, among others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. 
Contact UsShruti Thakur [email protected]+1(919)321-6187 www.delveinsight.com 
Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg
 
View original content:https://www.prnewswire.co.uk/news-releases/bispecific-antibody-clinical-trial-pipeline-appears-robust-with-250-key-pharma-companies-actively-working-in-the-therapeutics-segment–delveinsight-301868690.html

Continue Reading

Artificial Intelligence

Life Science Equipment Market to be Worth $97.96 Billion by 2031 – Exclusive Report by Meticulous Research®

Published

on

life-science-equipment-market-to-be-worth-$97.96-billion-by-2031-–-exclusive-report-by-meticulous-research

REDDING, Calif., May 20, 2024 /PRNewswire/ — According to a new market research report titled, ‘Life Science Equipment Market Size, Share, Forecast, & Trends Analysis By Technology (Spectroscopy, Microscopy, Chromatography (HPLC, GC, TLC), PCR, Immunoassay, Sequencing, Flow Cytometry, Microarray, Centrifuge) End User – Global Forecast to 2031,’ published by Meticulous Research®, the life science equipment market is projected to reach $97.96 billion by 2031, at a CAGR of 6.3% from 2024 to 2031.

Download Sample Report Now- https://www.meticulousresearch.com/download-sample-report/cp_id=3937 
Life sciences encompass a wide range of fields, including biology, biochemistry, genetics, pharmacology, and many more. Laboratory equipment plays a critical role in conducting experiments, collecting data, and analyzing samples to further scientific research and advance our understanding of living organisms and their underlying mechanisms. Equipment is also necessary for quality checks and validation of manufactured drugs and biologics in the life sciences industry. The growth of the life sciences industry is driving the adoption of life sciences and laboratory equipment.
The growth of this market is attributed to several factors, including increasing pharmaceutical and biotech R&D expenditures, government initiatives supporting life sciences R&D, the increasing prevalence of chronic and infectious diseases, and growth in initiatives to control environmental pollution. Additionally, the growth in genomics and proteomics, the increasing awareness and growing adoption of personalized medicines, increasing automation and digitalization in the life sciences industry, and the increasing focus on food safety and quality are expected to provide significant opportunities for players operating in the market.
The report offers a competitive landscape based on an extensive assessment of the leading players’ product portfolios and geographic presence and the key growth strategies adopted by them in the last three to four years. In recent years, the life science equipment market witnessed several product launches, product enhancements, product approvals, partnerships, agreements, & collaborations, acquisitions, and expansions.
The key players operating in the life science equipment market are Agilent Technologies, Inc. (U.S.), Becton, Dickinson, and Company (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Danaher Corporation (U.S.), F. Hoffmann LA-Roche AG (Switzerland), PerkinElmer, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Waters Corporation (U.S.), Bruker Corporation (U.S.), Shimadzu Corporation (Japan), Siemens Healthineers AG (Germany), Eppendorf SE (Germany), Sartorius AG (Germany), and QIAGEN N.V. (Netherlands).
Get a Glimpse Inside: Request Sample Pages- https://www.meticulousresearch.com/request-sample-report/cp_id=3937 
Growing Awareness and Adoption of Personalized Medicine to Offer Opportunities for Players Operating in the Life Science Equipment Market
Personalized medicine, also known as precision medicine, is an emerging approach to patient care. Physicians choose a treatment method based on the patient’s genetic makeup (also considering genetic changes resulting from a disease) and lifestyle habits. It is an emerging disease treatment and prevention approach that considers individual variability in genes, environment, and lifestyle.
Precision medicine can remove the need for guesswork, variable diagnostic ability, and treatment strategies based on generalized demographics. Moreover, precision medicine enables a more holistic view of an individual patient. Precision medicine for clinical workflows helps facilitate more predictive and preventive care by bringing targeted therapies. There has been an increase in the adoption of personalized medicine in recent years. For instance, according to the Personalized Medicine Coalition, the share of personalized medicine has increased steadily in the total drugs approved in the U.S. by the FDA, from 28% in 2015 to 35% in 2021. The increasing awareness and adoption of personalized medicine are driving the demand for specialized laboratory equipment and technologies that enable precise and accurate genetic and molecular analysis.
Personalized medicine heavily relies on genetic testing, sequencing, analysis of genetic, genomic, and proteomic information, and biomarker identification and validation. This necessitates the use of advanced laboratory equipment, such as DNA sequencers, gene sequencers, PCR machines, real-time PCR systems, next-generation sequencers, mass spectrometers, immunoassay analyzers, and chromatography systems, to accurately derive the necessary results.
The life science equipment market is segmented by Technology [Spectroscopy, Microscopy, Chromatography, Lab Automation, Immunoassay Analyzers, PCR, Sequencing, Flow Cytometry, Incubators, Microarray, Centrifuges, Electrophoresis, and Other Equipment], End User [Pharmaceutical and Biotechnology Industry, Academic & Research Institutes, Hospitals and Diagnostic Laboratories, Analytical Testing Laboratories, Agriculture and Food Industry, Forensic Laboratories, and Other End Users), and Geography. The study also evaluates industry competitors and analyzes the regional and country-level markets. (Note: Apart from primary segmentation, Spectroscopy, Microscopy, Chromatography, Lab Automation, Immunoassay Analyzer, PCR, Sequencing, Flow Cytometry, Microarray, Centrifuges, and Electrophoresis have further level segmentation).
Have Specific Research Needs? Request a Customized Report-https://www.meticulousresearch.com/request-customization/cp_id=3937 
Among the technologies included in the report, in 2024, the spectroscopy segment is expected to account for the largest share of 22% of the life science equipment market. The spectroscopy segment is further sub-segmented into molecular spectroscopy, atomic spectroscopy, mass spectrometry, and software. In 2024, the molecular spectroscopy segment is expected to account for the largest share of the spectroscopy market. Molecular spectroscopy is used to determine the composition of a material in an unknown chemical composition. It is used in various applications across food & beverage, environmental screening, pharmaceutical, and biotech industries. Therefore, the wide range of applications of molecular spectroscopy coupled with the growth of the life sciences industry, especially the pharmaceutical and biotech sectors, contribute to the large market share of this segment.
Among the end users included in the report, in 2024, the pharmaceutical and biotechnology industry segment is expected to account for the largest share of 32% of the life science equipment market. The largest share is contributed by several factors, including the increased demand for new drugs and therapies leading to extensive research and development activities, the need for technologically advanced equipment in the pharmaceutical and biotech industries, the rise in funding and investments in the pharmaceutical and biotech industry, and increased healthcare expenditure.
Among the geographies included in the report, in 2024, North America is expected to account for the largest share of 41% of the life science equipment market. North America’s major market share is attributed to the presence of key players, its well-established life science industry, and substantial spending on R&D activities by pharmaceutical and biotech companies. The U.S. is home to global top-ranking pharmaceutical companies. Companies like Johnson & Johnson, Pfizer, AbbVie Inc., Merck, and Bristol Myers Squibb are headquartered in the U.S. These companies have high R&D expenditure at increasing at a high rate each year. For example, Johnson & Johnson spent USD 14.7 billion on research and development in 2021, with a 21% increase over 2020.
Brows In-depth Report- https://www.meticulousresearch.com/product/life-science-equipment-market-3937 
Scope of the Report:
Life Science Equipment Market Assessment—by Technology
SpectroscopyMolecular SpectroscopyUV/Vis SpectroscopyNuclear Magnetic Resonance (NMR)Near-Infrared (NIR) SpectroscopyInfrared (IR) SpectroscopyRaman SpectroscopyPolarimeters and RefractometersFluorescence & Luminescence SpectroscopyOther Molecular Spectroscopy TechnologiesNote: Other molecular spectroscopy technologies segment includes Raman spectroscopy, ellipsometry, and color measurement
Mass SpectrometryQuadrupole LC/MSTime of Flight LC/MS (Q-TOF & LC-TOF)Gas Chromatography-Mass Spectrometry (GC/MS)Fourier Transform Mass Spectrometry (FT/MS)Matrix-Assisted Laser Desorption/Ionization-Time of Flight Mass Spectroscopy (MALDI-TOF MS)Portable and In-Field Mass SpectroscopyTandem Mass Spectroscopy (MS/MS)Ion Trap Mass Spectroscopy (LC/MS)Atomic SpectroscopyAtomic Absorbance Spectroscopy (AAS)X-Ray Fluorescence (XRF) SpectroscopyX-Ray Diffraction (XRD) SpectroscopyOther Atomic Spectroscopy TechnologiesNote: Other atomic spectroscopy technologies segment includes inductively coupled plasma (ICP) spectroscopy, glow discharge spectroscopy, and arc/spark optical emission spectroscopy
Spectroscopy SoftwareMicroscopyElectron MicroscopyOptical MicroscopyScanning Probe MicroscopyOther MicroscopyMicroscopy SoftwareChromatographyHigh-Performance Liquid Chromatography (HPLC)Gas Chromatography (GC)Low Pressure Liquid Chromatography (LPLC)Flash ChromatographyThin Layer Chromatography (TLC)Ion ChromatographySupercritical Fluid Chromatography (SFC)Chromatography SoftwareLab AutomationAutomated WorkstationsRobotic SystemsAutomated Storage and Retrieval Systems (ASRS)Lab Automation SoftwareImmunoassay AnalyzersChemiluminescence ImmunoassayFluorescence ImmunoassayRadioimmunoassay (RIA)Colorimetric ImmunoassayOther Immunoassay AnalyzersImmunoassay SoftwarePCRRT-PCRConventional PCRDigital PCRPCR SoftwareSequencingFlow CytometryCell-Based Flow CytometersBead-Based Flow CytometersFlow Cytometry SoftwareIncubatorsMicroarrayDNA MicroarraysProtein MicroarrayTissue ArrayOther MicroarraysMicroarray SoftwareNote: Other microarrays segment includes glycan microarray, carbohydrate microarray, and chemical compounds microarrays
CentrifugesCentrifuges, by TypeDevicesMultipurpose CentrifugesMicrocentrifugesMini centrifugesUltracentrifugesOther CentrifugesCentrifuge AccessoriesCentrifuges, by ModelBenchtop CentrifugesFloor-standing CentrifugesCentrifuges, by ApplicationResearch ApplicationsGenomicsMicrobiologyCellomics ProteomicsClinical ApplicationsDiagnosticsBlood Processing and ScreeningOther ApplicationsElectrophoresisGel ElectrophoresisCapillary ElectrophoresisGel Documentation Systems and SoftwareOther EquipmentNote: Other equipment segment includes autoclaves, stirrers & shakers, mixers, baths, hot plates, ovens & furnaces, and balances
Life Science Equipment Market Assessment —by End User
Pharmaceutical and Biotechnology IndustryAcademic & Research InstitutesHospitals and Diagnostic LaboratoriesAnalytical Testing LaboratoriesAgriculture and Food IndustryForensic LaboratoriesOther End UsersNote: Other end users include blood banks and industries, such as cosmetics, chemicals, oil & gas, electronics & semiconductors, automotive, aerospace, ceramics, plastics, rubber, and paints & coatings
Life Science Equipment Market Assessment —by Geography
North AmericaU.S.CanadaEuropeGermanyU.K.FranceItalySpainSwitzerlandRest of Europe (RoE)Asia-Pacific (APAC)ChinaJapanIndiaSouth KoreaRest of APAC (RoAPAC)Latin AmericaBrazilMexicoRest of LATAM (RoLATAM)Middle East & AfricaSaudi ArabiaUAERest of Middle East & Africa (RoMEA)Unlock Opportunities: Buy Now- https://www.meticulousresearch.com/Checkout/26911858 
Related Reports:
Genomics Market by Offering (Systems, Consumables, Software, Services), Technology (Sequencing, Microarray, PCR), Application (Diagnostics, Life Science Research), End User (Pharmaceutical Companies, Hospitals, Academic Institutes, CRO) – Global Forecast to 2030
NGS Automation Market by Product (Platform, Consumables), Sequencing Type (Whole Genome, Exome, Targeted), Application (Drug Discovery, Diagnostics), End User (Hospitals, Diagnostic Laboratories, Pharmaceutical, Academic) – Global Forecast to 2029
Liquid Handling Systems Market by Type (Automated, Electronic, Manual), Product (Pipette, Consumables, Burette, Software, Microplate), Application (Drug Discovery, Cancer & Genomics, Clinical), End User (Hospital, Diagnostic Lab) – Global Forecast to 2029
High-Performance Liquid Chromatography (HPLC) Market by Product (Instruments [Systems, Detectors], Consumables [Columns, Tubes], Accessories, Software), Application (Forensics, Diagnostics), End User (Research, Pharmaceuticals) – Global Forecast to 2030
Next Generation Sequencing Market by Type (Consumables, NGS Platform, Software), Sequencing Type (Whole Genome, Targeted), Technology (Sequencing by Synthesis, Sequencing by Ligation), Application (Clinical, Research), End User – Global Forecasts to 2030
Chromatography Reagents Market by Type (GC, LC, TLC), Product (Solvents, Buffers, Reagents), Separation (Adsorption, Partition, Affinity), Application (Pharma, Forensic, Environmental, Cosmeceuticals, Diagnostics, QC), End User – Global Forecast to 2030
Related Blogs:
Top 10 Companies in Life Science Equipment Market
Life Science Equipment: The Role of Various Technologies
About Meticulous Research®
Meticulous Research® was founded in 2010 and incorporated as Meticulous Market Research Pvt. Ltd. in 2013 as a private limited company under the Companies Act, 1956. Since its incorporation, the company has become the leading provider of premium market intelligence in North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa.
The name of our company defines our services, strengths, and values. Since the inception, we have only thrived to research, analyze, and present the critical market data with great attention to details. With the meticulous primary and secondary research techniques, we have built strong capabilities in data collection, interpretation, and analysis of data including qualitative and quantitative research with the finest team of analysts. We design our meticulously analyzed intelligent and value-driven syndicate market research reports, custom studies, quick turnaround research, and consulting solutions to address business challenges of sustainable growth.
Contact:Mr. Khushal BombeMeticulous Market Research Inc.1267 Willis St, Ste 200 Redding,California, 96001, U.S.USA: +1-646-781-8004Europe: +44-203-868-8738APAC: +91 744-7780008Email- [email protected] Visit Our Website: https://www.meticulousresearch.com/Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-researchContent Source: https://www.meticulousresearch.com/pressrelease/348/life-science-equipment-market-2031
Logo: https://mma.prnewswire.com/media/1757980/Meticulous_Research_Logo_1.jpg
 

View original content:https://www.prnewswire.co.uk/news-releases/life-science-equipment-market-to-be-worth-97-96-billion-by-2031—exclusive-report-by-meticulous-research-302150104.html

Continue Reading

Artificial Intelligence

Public Safety and Security Market to Reach $ 514.1 Billion by 2031- Exclusive Report by Meticulous Research®

Published

on

public-safety-and-security-market-to-reach-$-514.1-billion-by-2031-exclusive-report-by-meticulous-research

REDDING, Calif., May 20, 2024 /PRNewswire/ — According to a new market research report titled, ‘Public Safety and Security Market by Offering (Safety Devices, Safety Software, Safety Services), Technology (IoT, AI, Cloud Computing, ML), Application (Data Gathering, Mapping, and 3D Imaging), End Use (Warehouses & Depots, Workplaces, Shopping Malls & Retail Stores) and Geography, the global public safety and security market is expected to reach $514.1 billion by 2031 from an estimated $ 234.2 billion in 2024, at a CAGR of 11.9% during the forecast period (2024–2031).

Download Sample Report Now- https://www.meticulousresearch.com/download-sample-report/cp_id=5661
The growth of the public safety and security market is driven by the growing utilization of AI, ML, and analytics technologies in public safety and security applications, increasing awareness and initiatives for public safety and security, and government focus on managing the needs of the rising urban population. However, the significant initial investments required to implement public safety and security solutions restrain the growth of this market. The integration of cloud computing and big data analytics in public safety and security solutions and the rising incidence of terrorism and security breaches are expected to generate market growth opportunities. However, the complexities in implementing advanced public safety and security systems and the rising cases of data theft are major challenges for market stakeholders.
The global public safety and security market is segmented by offering, technology, application, end use, and geography. The study also evaluates industry competitors and analyses the country and regional-level markets.
Based on offering, the global public safety and security market is segmented into safety devices, safety software, and safety services. In 2024, the safety services segment is expected to account for the largest share of 50% of the public safety and security market. The large market share of this segment is attributed to the increasing demand for specialized safety services to address specific safety and security challenges. Safety services such as critical infrastructure security, emergency medical, firefighting, and disaster management services are critical in ensuring the safety and well-being of citizens and critical assets.
Based on technology, the global public safety and security market is segmented into the internet of things, artificial intelligence, cloud computing, machine learning, cybersecurity, and other technologies. In 2024, the internet of things segment is expected to account for the largest share of the global public safety and security market. The large share of the segment is attributed to the rising demand for real-time data insights and improved situational awareness.
Get a Glimpse Inside: Request Sample Pages- https://www.meticulousresearch.com/request-sample-report/cp_id=5661
Based on application, the global public safety and security market is segmented into data gathering, mapping and 3D imaging, threat detection, security and incident management, monitoring, fire and explosion examination, network security, and other applications. In 2024, the security and incident management segment is expected to account for the largest share of 18.5% of the public safety and security market. The large market share of this segment is attributed to the need to respond effectively to emergencies, the increasing adoption of smart city technologies, and the integration of IoT devices.
Based on end use, the global public safety and security market is segmented into warehouses & depots, workplaces, shopping malls & retail stores, schools & universities, hospitals & healthcare, residential, transportation, and other end uses. In 2024, the transportation segment is expected to account for the largest share of the global public safety and security market. The segment is estimated to contribute a revenue of USD 31.8 billion by 2024 in public safety and security market. The large share of this segment is attributed to the growing concern of terrorist threats and passenger safety. Advances in contactless ticketing and facial recognition for identity verification are driving the adoption of modern transportation security solutions. Furthermore, the implementation of AI-based video analytics for crowd monitoring contributes to the growth of this segment.
Have Specific Research Needs? Request a Customized Report- https://www.meticulousresearch.com/request-customization/cp_id=5661
Based on geography, the public safety and security market is segmented into North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. In 2024, North America is expected to account for the largest share of 40% of the public safety and security market. The North America public safety and security market is estimated to be worth USD 95.4 billion in 2024. The large share of this region is attributed to the rising adoption of digital technology and data due to the growing need for improving decision-making, promoting digital inclusivity and equity, creating a collaborative ecosystem, prioritizing citizen safety and health, establishing trust and transparency, and developing resilience and adaptability to manage change effectively.
However, the Europe public safety and security market is slated to register the highest CAGR of the global public safety and security market during the forecast period.
The key players operating in the global public safety and security market are Hexagon AB (Sweden), Fujitsu Ltd. (Japan), Robert Bosch GmbH (Germany), Atos SE (France), Cisco Systems, Inc. (U.S.) Saab AB (Sweden), Airbus SE (Netherlands), Siemens AG (Germany), Intel Corporation (U.S.), Fotokite AG (Switzerland), CityShob (Israel), 3xLOGIC (U.S.), L3Harris Technologies, Inc. (U.S.), OnSolve (U.S.) and Haystax (U.S.).
Brows In-depth Report- https://www.meticulousresearch.com/product/public-safety-and-security-market-5661 
Scope of the Report
Public Safety and Security Market, by Offering
Safety ServicesManaged ServicesDisaster Management ServicesCritical Infrastructure Security ServicesEmergency Medical ServicesFirefighting ServicesOther Managed ServicesProfessional ServicesSafety DevicesSurveillance CamerasSensorsRadarLiDARGeodetic SensorsGeotechnical and environmental sensorsOther SensorsBiometric and Authentication DevicesSafety AlarmsIntruder Detection DevicesCritical Communication DevicesOther Safety DevicesSafety SoftwareGeographic Information SystemsAccess Control SoftwareBuilding Management SoftwareVehicle Recognition SoftwareBehavior Analytics softwareOther Safety SoftwarePublic Safety and Security Market, by Technology
Internet of ThingsCybersecurityCloud ComputingMachine LearningArtificial IntelligenceOther TechnologiesPublic Safety and Security Market, by Application
Security and Incident ManagementThreat DetectionFire and Explosion ExaminationNetwork SecurityMonitoringData GatheringMapping and 3D ImagingOther ApplicationsPublic Safety and Security Market, by End Use
TransportationRoadwaysRailwaysAirwaysWaterwaysWorkplacesShopping malls & Retail storesResidentialHospitals & HealthcareWarehouses & DepotsSchools & UniversitiesOther End UsesPublic Safety and Security Market, by Geography       
North AmericaU.S.CanadaAsia-PacificChinaJapanIndiaSouth KoreaTaiwanRest of Asia-PacificEuropeGermanyU.K.FranceItalySpainRest of EuropeLatin AmericaMiddle East & AfricaUnlock Opportunities: Buy Now- https://www.meticulousresearch.com/Checkout/39886758
Related Reports:
Smart Cities Market by Solution (Smart Citizen Services, Smart Environment, Smart Buildings, Smart Transportation, Smart Utilities, Other Smart Solutions), Component (Hardware, Software, Services), Technology, Geography – Global Forecast to 2030
Smart Transportation Market by Transportation Mode, Product Type (Solutions & Services), Application (Mobility as a Service, Route Information, Route Guidance, Public Transport, Transit Hubs, Connected Cars), and Region – Global Forecast to 2028
Cybersecurity Market by Type (Network Security, Endpoint Security, Application Security, Cloud Security), Solution (Unified Threat Management, Antimalware, Firewall, Disaster Recovery, Web Filtering, DDS Management, Encryption) – Global Forecast to 2027
Security Analytics Market, by Offering, Deployment Mode, Security Type (Network, Cloud, Endpoint), Platform, Organization Size, Application, End-use Industry (Healthcare, Logistics, Government, Retail), and Geography—Global Forecasts to 2029
About Meticulous Research®
Meticulous Research® was founded in 2010 and incorporated as Meticulous Market Research Pvt. Ltd. in 2013 as a private limited company under the Companies Act, 1956. Since its incorporation, the company has become the leading provider of premium market intelligence in North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa.
The name of our company defines our services, strengths, and values. Since the inception, we have only thrived to research, analyze, and present the critical market data with great attention to details. With the meticulous primary and secondary research techniques, we have built strong capabilities in data collection, interpretation, and analysis of data including qualitative and quantitative research with the finest team of analysts. We design our meticulously analyzed intelligent and value-driven syndicate market research reports, custom studies, quick turnaround research, and consulting solutions to address business challenges of sustainable growth.
Contact:Mr. Khushal BombeMeticulous Market Research Inc.1267 Willis St, Ste 200 Redding,California, 96001, U.S.USA: +1-646-781-8004Europe : +44-203-868-8738APAC: +91 744-7780008Email- [email protected] Visit Our Website: https://www.meticulousresearch.com/Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-researchContent Source: https://www.meticulousresearch.com/pressrelease/895/public-safety-and-security-market-2031
Logo: https://mma.prnewswire.com/media/1757980/Meticulous_Research_Logo_1.jpg
 

View original content:https://www.prnewswire.co.uk/news-releases/public-safety-and-security-market-to-reach–514-1-billion-by-2031–exclusive-report-by-meticulous-research-302150049.html

Continue Reading

Artificial Intelligence

ClearBlade & SAS have been positioned as the leaders in the 2024 SPARK Matrix™ for the global Internet of Things (IoT) Edge Analytics platform market by Quadrant Knowledge Solutions

Published

on

clearblade-&-sas-have-been-positioned-as-the-leaders-in-the-2024-spark-matrix™-for-the-global-internet-of-things-(iot)-edge-analytics-platform-market-by-quadrant-knowledge-solutions

Shared market leadership underscores strong partnership in Edge AI applications
The Quadrant Knowledge Solutions SPARK Matrix™ provides competitive analysis and ranking of the leading Internet of Things (IoT) edge analytics platform vendors.ClearBlade’s comprehensive technology and customer experience management have received strong ratings for technology excellence and customer impact.SAS® Event Stream Processing, a sophisticated analytics platform tailored for edge computing, offers organizations the ability to process data close to its origin, facilitating faster and more informed decisions.MIDDLETON, Mass., May 20, 2024 /PRNewswire/ — Quadrant Knowledge Solutions announced today that it named ClearBlade and SAS 2024 technology leaders in its SPARK Matrix: IoT Edge Analytics Platforms.

Quadrant Knowledge Solutions’ SPARK Matrix includes a detailed analysis of the global market dynamics, major trends, vendor landscape, and competitive positioning. The study provides a competitive analysis and ranking of the leading technology vendors. It offers strategic information to users for evaluating the capabilities, competitive differentiation, and market positions of various vendors.
Comments on the News
“To streamline the development of IoT platforms, ClearBlade offers a comprehensive suite of developer tools, such as a web-based Integrated Development Environment (IDE), Command-Line Interface (CLI), and a devkit for local development. The company’s API-first approach, with local development options and edge runtime support, empowers developers to create and test applications locally, thereby enhancing their productivity. ClearBlade’s comprehensive rules processing engine enables analytics and action triggering based on predefined rules. The engine is supported by full code runtime and Open Neural Network Exchange (ONNX) frameworks for edge AI executions. ClearBlade’s platform ensures fault tolerance and data integrity through its robust synchronization capabilities, while its extensive support for various protocols and seamless integration with third-party applications enhance interoperability and expand analytical possibilities for IoT solutions. The company has received strong ratings across parameters of technology excellence and customer impact and has been positioned as a leader in the 2024 SPARK Matrix of the IoT Edge Analytics Platform Market,” said Quadrant Knowledge Solutions Analyst Vyshak K.Download report: https://quadrant-solutions.com/market-research/spark-matrix-iot-edge-analytics-platforms-q2-2024-3240
“We’re honored to be named the leader in IoT Edge Analytics Platforms alongside our partner SAS,” said ClearBlade Founder & CEO Eric Simone. “Our customers rely on our flexible IoT Edge application to not only connect their assets, but also to leverage machine data for real-time insights that improve safety, efficiency and sustainability. A great example of this is our solar farm work at SAS – we’re thrilled to share a leadership position with our innovative, valued partner.””With AI and IoT analytics offered by SAS and partners like ClearBlade, organizations in manufacturing, energy, transportation and government can optimize operations, enhance worker safety, improve maintenance strategies, reduce emissions, mitigate flooding and much more,” said Jason Mann, Vice President of IoT at data and AI leader SAS. “The latest SPARK Matrix for IoT edge analytics platforms underscores the leadership of SAS and ClearBlade and the value we provide to our customers.”Quadrant Knowledge Solutions defines the IoT edge analytics platform as “a software platform designed to collect, process, and analyze data generated by Internet of Things (IoT) devices at the edge of a network—close to the source where data is generated—and derive insights from it. The platform enables real-time or near-real-time analysis and decision-making without the need to send data to a centralized location for processing. By performing analytics at the edge, these platforms can reduce latency, bandwidth usage, and dependency on cloud services, making them ideal for use cases where real-time responsiveness, data privacy, or intermittent connectivity are critical factors. Overall, an IoT edge analytics platform empowers organizations to derive the potential of their IoT deployments by offering actionable insights and intelligence directly at the edge of the network. The key capabilities of an IoT edge analytics platform include data streaming, data management, edge analytics, fault tolerance and reliability, developer tools, and integration and interoperability.”
Additional Resources:
Download SPARK Matrix: IoT Edge Analytics PlatformsAbout ClearBlade
ClearBlade is the industry leading IoT, Edge AI and connected Digital Twins provider. On a mission to make the world more efficient, safer and sustainable, our customers bring their IoT visions to life with our award-winning, secure, flexible, autonomous, real-time and scalable software: IoT Core, Enterprise IoT, Edge AI and Intelligent Assets. Highly tailored to the buildings, transportation and energy industries, our software connects with any device, sensor, edge, cloud, or on-premise system via any protocol. The result is a highly flexible, transformative IoT solution … deployed, operational and driving ROI within weeks. For more information, please visit www.clearblade.com
Media ContactDanielle Schulz-Behrend, Marketing Director, ClearBladeEmail: [email protected]: (+1) (866) 999-3343
About Quadrant Knowledge Solutions
Quadrant Knowledge Solutions is a global advisory and consulting firm focused on helping clients achieve business transformation goals with Strategic Business and Growth Advisory Services. At Quadrant Knowledge Solutions, our vision is to become an integral part of our client’s business as a strategic knowledge partner. Our research and consulting deliverables are designed to provide comprehensive information and strategic insights for helping clients formulate growth strategies to survive and thrive in ever-changing business environments.
For more available research, please visit https://quadrant-solutions.com/market-research/
Media ContactMr. Ajinkya IngleQuadrant Knowledge SolutionsRegus Business Center35 Village Road, Suite 100Middleton Massachusetts 01949United StatesEmail: [email protected]: (+1) 978-344-2770Content Source: https://quadrant-solutions.com/press-release/clearblade-sas-have-been-positioned-as-the-leaders-in-the-2024-spark-matrix-for-the-global-internet-of-things-iot-edge-analytics-platform-market-by-quadrant-knowledge-solutions-610 Connect with us on LinkedIn- https://www.linkedin.com/company/quadrant-knowledge-solutions/
Logo: https://mma.prnewswire.com/media/746706/1470558/Quadrant_Knowledge_Solutions_Logo.jpg
 

View original content:https://www.prnewswire.co.uk/news-releases/clearblade–sas-have-been-positioned-as-the-leaders-in-the-2024-spark-matrix-for-the-global-internet-of-things-iot-edge-analytics-platform-market-by-quadrant-knowledge-solutions-302150197.html

Continue Reading
Advertisement
Advertisement

Latest News

Trending